Abcb1 and abcg2 control brain accumulation and intestinal disposition of the novel ros1/trk/alk inhibitor repotrectinib, while oatp1a/1b, abcg2, and cyp3a limit its oral availability

HIGHLIGHTS

  • who: Wenlong Li et al. from the Division of Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Faculty of Science, Utrecht University, Universiteitsweg, CG Utrecht, The Netherlands have published the research work: ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability, in the Journal: Pharmaceutics 2021, 13, x FOR PEER REVIEW of /2021/
  • what: This study shows that mouse Oatp1a/1b transporters could substantially control plasma exposure, liver distribution and intestinal disposition of repotrectinib.
  •  

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?